middle.news
Chimeric Therapeutics Achieves 60% Complete Response in AML Trial
9:42am on Monday 27th of April, 2026 AEST
•
Healthcare
Read Story
Chimeric Therapeutics Achieves 60% Complete Response in AML Trial
9:42am on Monday 27th of April, 2026 AEST
Key Points
60% CR/CRi rate in 25 high-risk AML patients
Combination therapy with azacitidine and venetoclax well tolerated
Trial ongoing at MD Anderson Cancer Center
Standard care response rates typically 20-30%
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Chimeric Therapeutics (ASX:CHM)
OPEN ARTICLE